APA (7th ed.) Citation

Chauvin, C., Levillayer, L., Roumier, M., Nielly, H., Roth, C., Karnam, A., . . . Sakuntabhai, A. (2023). Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants. iScience, 26(3), 106124. https://doi.org/10.1016/j.isci.2023.106124

Chicago Style (17th ed.) Citation

Chauvin, Camille, et al. "Tocilizumab-treated Convalescent COVID-19 Patients Retain the Cross-neutralization Potential Against SARS-CoV-2 Variants." IScience 26, no. 3 (2023): 106124. https://doi.org/10.1016/j.isci.2023.106124.

MLA (9th ed.) Citation

Chauvin, Camille, et al. "Tocilizumab-treated Convalescent COVID-19 Patients Retain the Cross-neutralization Potential Against SARS-CoV-2 Variants." IScience, vol. 26, no. 3, 2023, p. 106124, https://doi.org/10.1016/j.isci.2023.106124.